Company news

Axsome Therapeutics, Inc. news in 2020

Axsome Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

December 30, 2020

Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine

December 30, 2020

Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation

December 7, 2020

Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression

December 1, 2020

Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder

November 30, 2020

Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

November 4, 2020

Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform

November 3, 2020

Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform

November 3, 2020

Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer’s Disease Agitation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

November 2, 2020

Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020

October 27, 2020

Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital

September 28, 2020

Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine

September 23, 2020

Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting

September 20, 2020

Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation

September 16, 2020

Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder

September 13, 2020

Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress

September 9, 2020

Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

September 7, 2020

Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer’s Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting

August 30, 2020

Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting

August 27, 2020

Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine

August 19, 2020

Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

August 9, 2020

Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program

August 9, 2020

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy

August 4, 2020

Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020

July 29, 2020

Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder

July 12, 2020

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

June 25, 2020

Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting

May 28, 2020

Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually

May 25, 2020

Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update

May 7, 2020

Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020

April 29, 2020

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation

April 26, 2020

Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine

April 5, 2020

Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications

March 29, 2020

Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation

March 19, 2020

Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

March 11, 2020

Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer

March 4, 2020

Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine

February 19, 2020

Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

January 21, 2020

Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

January 12, 2020

Calls in 2020

Decks in 2020